Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Peony Yu"'
Autor:
Robert Provenzano, Steven Fishbane, Lynda Szczech, Robert Leong, Khalil G. Saikali, Ming Zhong, Tyson T. Lee, Mark T. Houser, Lars Frison, John Houghton, Dustin J. Little, Kin-Hung Peony Yu, Thomas B. Neff
Publikováno v:
Kidney International Reports, Vol 7, Iss 3, Pp 665- (2022)
Externí odkaz:
https://doaj.org/article/1830ee1a2e3b4106adf197ccb3c7ea4a
Autor:
Richeldi, Luca *, Fernández Pérez, Evans R, Costabel, Ulrich, Albera, Carlo, Lederer, David J, Flaherty, Kevin R, Ettinger, Neil, Perez, Rafael, Scholand, Mary Beth, Goldin, Jonathan, Peony Yu, Kin-Hung, Neff, Thomas, Porter, Seth, Zhong, Ming, Gorina, Eduard, Kouchakji, Elias, Raghu, Ganesh
Publikováno v:
In The Lancet Respiratory Medicine January 2020 8(1):25-33
Autor:
Sohan Dua, Cameron Liu, Charles Bradley, Khalil G. Saikali, Robert Leong, Dylan Steer, Lynda A. Szczech, Edouard R Martin, Marializa V. Bernardo, Kin-Hung Peony Yu, Chaim Charytan, Meraf Eyassu, Roberto Manllo-Karim, Moustafa A. Moustafa, Gopal Saha
Publikováno v:
Kidney International Reports
Introduction Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a8e3c417ba36559408f49c886119b5a
https://doi.org/10.1016/j.ekir.2021.04.007
https://doi.org/10.1016/j.ekir.2021.04.007
Autor:
Willis Chou, Sung Gyun Kim, Lynda A. Szczech, Andres A. Cadena, Daniel W. Coyne, Anatole Besarab, Robert Leong, Moustafa A. Moustafa, Tyson Lee, Simon D. Roger, Meraf Eyassu, Kin-Hung Peony Yu, Tak Mao Chan, Sug Kyun Shin, Charles Bradley, Khalil G. Saikali
Publikováno v:
Kidney International Reports
Introduction Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and improves iron metabolism. We assessed the efficacy and tolerability of roxadustat in patients with chronic kidney disease (CKD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::471632625ebd6cf524b6d0552d64463f
https://doi.org/10.1016/j.ekir.2020.11.034
https://doi.org/10.1016/j.ekir.2020.11.034
Autor:
Charles Bradley, Lona Poole, Robert Leong, Anatole Besarab, Liubov Eremeeva, Lynda A. Szczech, Meraf Eyassu, Thomas B. Neff, Kin-Hung Peony Yu, Evgeny Shutov, Cameron Liu, Robert Provenzano, Gopal Saha, Svitlana Korneyeva
Publikováno v:
Nephrology Dialysis Transplantation. 36:1717-1730
Background We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the treatment of chronic kidney disease-related anemia in patients new to dialysis. Methods HIMALAYAS was a Phase 3, open-label, epoetin alfa-controlled trial. Elig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfb75680793426ec819f4ff73c2ac112
https://doi.org/10.1093/ndt/gfab051
https://doi.org/10.1093/ndt/gfab051
Autor:
James Chou, Thomas B. Neff, James A. Tumlin, Stefan Hemmerich, R. Zabaneh, Robert Provenzano, K. H. Peony Yu
Publikováno v:
Journal of Clinical Pharmacology
Roxadustat (FG‐4592), an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, was evaluated in a phase 1b study in patients with end‐stage renal disease with anemia on hemodialysis. Seventeen patients, on e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcff0afc5a01e9ef37f2c3aa20428577
https://doi.org/10.1002/jcph.1648
https://doi.org/10.1002/jcph.1648
Autor:
Gopal Saha, Robert Leong, Kin-Hung Peony Yu, David H. Henry, Charles Bradley, Moshe Mittelman, Hetty E. Carraway, John A. Glaspy, Amy Zhou, Katharina Modelska, Rosemary Harrup, Pamela Bartels
Publikováno v:
American journal of hematologyREFERENCES. 97(2)
Anemia is the predominant cytopenia in myelodysplastic syndromes (MDS) and treatment options are limited. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia of chronic kidney disease in the UK,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89aae2a06185055db76ebbbd942da3e1
https://pubmed.ncbi.nlm.nih.gov/34724251
https://pubmed.ncbi.nlm.nih.gov/34724251
Autor:
Provenzano, Robert, Fishbane, Steven, Szczech, Lynda, Leong, Robert, Saikali, Khalil G., Zhong, Ming, Lee, Tyson T., Houser, Mark T., Frison, Lars, Houghton, John, Little, Dustin J., Peony Yu, Kin-Hung, Neff, Thomas B.
Publikováno v:
In Kidney International Reports March 2021 6(3):613-623
Autor:
Awad, Mark M., Devarakonda, Siddhartha, Yang, Jin-Li, Zhang, Yan, Wu, Lin, Hu, Jie, Wang, Zhe-Hai, Chen, Jing-Hua, Fan, Yun, Zhao, Jun, Fang, Jian, Song, Yong, Li, Xing-Ya, Perol, Maurice, Planchard, David, Garrido, Pilar, Lindsay, Colin, Moore, Melissa M., Bulotta, Alessandra, Costa, Enric Carcereny, Provencio, Mariano, Chih-Hsin Yang, James, Spigel, David, Nadal, Ernest, Peony Yu, Kin-Hung, Wu, Yi-Long
Publikováno v:
Journal of Thoracic Oncology; July 2024, Vol. 19 Issue: 7, Number 7 Supplement 1 pe45-e46, 2p
Autor:
Kin-Hung Peony Yu, Robert Provenzano, Lars Frison, John Houghton, Lynda A. Szczech, Dustin J. Little, Ming Zhong, Robert Leong, Steven Fishbane, Tyson Lee, Thomas B. Neff, Mark T. Houser, Khalil G. Saikali
Publikováno v:
Kidney International Reports
Introduction Erythropoiesis-stimulating agents are associated with increased cardiovascular risk when higher doses are used toward higher hematocrit targets. Patients new to dialysis are at higher risk for morbidity and mortality. Systematic evaluati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a54003ce8bf2b2602f2f04a1f084ab3
https://pubmed.ncbi.nlm.nih.gov/35257087
https://pubmed.ncbi.nlm.nih.gov/35257087